Home › Companies › PCSA

Processa Pharmaceuticals

PCSA Rare disease Lead: Phase 2 ★ Read the deep dive → 2 Biotech Distilled articles ↓

GI/Hepatology Oncology Renal Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (7 active programs)

NGC-Cap

PCS6422

Small Molecule Target: DPD

Breast Cancer Phase 2 oral

NGC-Iri

PCS11T

Small Molecule Target: SN38

Undisclosed indication Preclinical

PCS12852

Small Molecule Target: 5HT4

Gastroparesis Phase 2
Undisclosed indication

PCS499

Focal Segmental Glomerulosclerosis oral
IgA Nephropathy oral
Undisclosed indication

Biotech Distilled coverage (2)

2026-05-08 UPDATE: Processa Pharmaceuticals (PCSA) - The Cash Crash and the Crypto Doubling-Down 🔒 Paid
2026-04-11 Processa Pharmaceuticals (PCSA) - Scientific Deep Dive for PCS6422 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.